Magnolol Cancer Research Results

MAG, Magnolol: Click to Expand ⟱
Features:
Lignan found in bark of some magnolia species.
Magnolol (MAG) — a bioactive biphenolic compound from Magnolia officinalis
derived from the bark (roots and branches) of Magnolia species such as M. officinalis, M. obovata, and M. grandiflora
The two main bioactive compounds isolated from these plants are MAG (5,5ʹ-diallyl-2,2ʹ-dihydroxybiphenyl) and Honokiol (3,5ʹ-diallyl-4,2ʹ-dihydroxybiphenyl) (Fig. 1) which are phenolic regioisomers.
In the bark extracts of Magnolia plants, the composition of MAG ranges from 1 to 10%, while Honokiol comprises 1 to 5%
Magnolol is a biphenolic neolignan isolated from the bark of Magnolia officinalis. It is structurally related to honokiol and is studied for anti-inflammatory, antioxidant, antimicrobial, and neuroactive effects. In preclinical oncology models, magnolol is reported to modulate NF-κB, STAT3, PI3K/AKT, MAPK, Wnt/β-catenin, and redox pathways, with downstream effects on cell-cycle arrest, apoptosis, invasion/EMT, and angiogenesis. Oral bioavailability is limited and many cytotoxic concentrations reported in vitro are in the tens of µM range, often above typical systemic levels from standard supplementation.

Magnolol — a naturally occurring biphenolic neolignan and polyphenolic small molecule found primarily in the bark of Magnolia officinalis and related Magnolia species, including M. obovata. It is commonly abbreviated MAG or MG and is a structural regioisomer of honokiol. Magnolol has anti-inflammatory, redox-modulating, neuroprotective, and preclinical antineoplastic activity. Its cancer pharmacology is pleiotropic rather than attributable to a single molecular target, with prominent effects on mitochondrial apoptosis, PI3K/AKT/mTOR, NF-κB/STAT3, ROS, cell-cycle regulation, invasion/EMT, and angiogenesis.

Primary mechanisms (ranked):

  1. Mitochondrial apoptosis and mitochondrial dysfunction, including ↑ Bax/Bcl-2 ratio, ↑ cytochrome c release, ↑ caspase activation, ↓ mitochondrial membrane potential, and in some models MPTP opening.
  2. PI3K/AKT/mTOR survival signaling suppression, contributing to reduced proliferation, survival, invasion, and treatment resistance.
  3. NF-κB and STAT3 suppression, reducing pro-survival, inflammatory, EMT, and stemness-related transcription.
  4. ROS elevation in multiple cancer models, particularly mitochondrial ROS, which can drive mitochondrial injury and apoptosis; magnolol can instead act as an antioxidant in non-malignant tissues.
  5. Cell-cycle arrest through modulation of cyclins, CDKs, p21, p27, and p53.
  6. Inhibition of invasion and EMT through effects on MMPs, E-cadherin, Snail/Slug, TGF-β/Smad, and related pathways.
  7. Suppression of HIF-1α/VEGF-mediated angiogenic signaling in selected tumor models.
  8. Wnt/β-catenin suppression in colorectal and other selected cancer models.
  9. Ca²⁺ dysregulation and mitochondrial signaling in selected cancer models, contributing to cytochrome-c release and apoptosis.
  10. Chemosensitization and radiosensitization in preclinical models, including reported enhancement of 5-FU, cisplatin, and radiation responses.
  11. NRF2-mediated antioxidant protection is primarily relevant to normal/non-malignant cells and should be considered a secondary, context-dependent mechanism rather than a universal anticancer mechanism.

Bioavailability / PK relevance: Magnolol is lipophilic and poorly water soluble, with substantial first-pass phase-II metabolism. After oral administration, glucuronide and sulfate conjugates predominate in circulation, whereas unconjugated magnolol can accumulate more substantially in tissues. Rapid glucuronidation and sulfation materially limit systemic free-magnolol exposure. Nanoparticles, micelles, nanosuspensions, lipid-based delivery systems, and structural derivatives have therefore been investigated to improve exposure.

In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately 10–100 µM magnolol, commonly tens of micromolar. These concentrations should not be assumed to be achievable as sustained free-magnolol plasma concentrations following conventional oral supplementation. Tissue exposure may exceed circulating unconjugated concentrations, but the exposure gap remains a major translational limitation.

Clinical evidence status: Preclinical for cancer treatment. Evidence includes extensive cell studies and multiple animal/xenograft models, but magnolol is not an established or approved anticancer therapy and there is no convincing human oncology efficacy evidence. Human experience is mainly with Magnolia officinalis extracts or multi-ingredient natural-health products for non-oncologic indications. Magnolia-containing natural health products are licensed in Canada, but this does not constitute approval of purified magnolol for cancer treatment.

major pathways and molecular targets involved in magnolol’s anticancer actions:
-Apoptosis: ↑ Bax, ↓ Bcl-2, ↑ cytochrome c, ↑ caspase-9, ↑ caspase-3
-Arrests cell cycle at G0/G1 or G2/M phase:↓ Cyclin D1, CDK4, CDK6, Cyclin B1, CDK1
-Inhibits NF-κB activation: ↓ IκBα, COX-2, TNF-α
-Inhibits PI3K, Akt, and mTOR phosphorylation
-Suppresses angiogenesis: ↓ Bcl-XL, Mcl-1, VEGF, cyclin D1
-Inhibits β-catenin nuclear translocation
-increase ROS production in tumor cells → triggers mitochondrial apoptosis
-Magnolol activates Nrf2 in normal cells → upregulates HO-1, NQO1: Protects normal tissue from oxidative stress during chemotherapy or inflammation.

Most in-vitro IC50 values fall in the 10–100 µM range, often above typical systemic exposure.

Magnolol Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis and MPTP Apoptosis ↑; Bax/Bcl-2 ↑; cytochrome c ↑; caspase-3/9 ↑; ΔΨm ↓; MPTP opening ↑ ↔ (model-dependent) R, G Mitochondrial cell-death execution One of the most reproducible anticancer phenotypes. Mitochondrial depolarization, fragmentation, ROS generation, and permeability transition have been reported in several cancer models.
2 PI3K AKT mTOR survival signaling PI3K ↓; p-AKT ↓; AKT ↓; mTOR ↓; p70S6K ↓ (model-dependent) ↔ or protective AKT signaling (context-dependent) R, G Growth and survival suppression Repeatedly implicated across prostate, gastric, cervical, bladder, and other tumor models.
3 NF-κB and STAT3 transcription NF-κB ↓; p-STAT3 ↓; survival and inflammatory targets ↓ NF-κB inflammatory signaling ↓ R, G Pro-survival transcription suppression NF-κB evidence is broad. Direct STAT3 evidence is more model-specific but important in NSCLC and oral cancer stemness models.
4 Mitochondrial ROS and oxidative stress ROS ↑; mtROS ↑; mitochondrial damage ↑; antioxidant capacity ↓ (model-dependent) ROS ↓; oxidative damage ↓ in many non-cancer models P, R Pro-oxidant tumor stress Magnolol is not uniformly pro-oxidant. Cancer-cell ROS elevation is well demonstrated in selected breast, renal, lung, and mitochondrial models, whereas antioxidant activity predominates in many normal-tissue studies.
5 Cell-cycle checkpoints Cell-cycle arrest ↑; Cyclin D1/B1 ↓; CDK1/2/4 ↓; p21 ↑; p27 ↑; p53 ↑ ↔ (generally) G Cytostasis G0/G1 or G2/M arrest occurs depending on tumor type and experimental conditions.
6 EMT invasion and metastasis Migration ↓; invasion ↓; MMP2/7/9 ↓; E-cadherin ↑; Snail/Slug ↓; EMT ↓ ↔ G Anti-invasive phenotype Multiple upstream mechanisms contribute, including PI3K/AKT/mTOR, NF-κB/STAT3, TGF-β/Smad, and Wnt signaling.
7 HIF-1α VEGF angiogenesis HIF-1α ↓; VEGF ↓; VEGFR2 signaling ↓; angiogenesis ↓ ↔ (context-dependent) R, G Hypoxia and angiogenesis suppression Particularly well characterized in hypoxic bladder cancer models; should not be generalized to every tumor type.
8 Wnt β-catenin signaling β-catenin nuclear translocation ↓; β-catenin/TCF transcription ↓; c-Myc ↓; MMP7 ↓; uPA ↓ ↔ R, G Proliferation and invasion suppression Strong mechanistic evidence exists in colorectal cancer cells and xenografts, but this is not a universal magnolol mechanism across all cancers.
9 Ca²⁺ mitochondrial signaling Intracellular Ca²⁺ ↑ (model-dependent); mitochondrial dysfunction ↑; cytochrome c release ↑ ↔ P, R Apoptotic signal amplification Reported in colon and liver cancer models. Mechanistically meaningful but less universally demonstrated than mitochondrial apoptosis or PI3K/AKT inhibition.
10 MAPK stress signaling ERK/JNK/p38 modulation (model-dependent) Inflammatory MAPK activation ↓ in several non-cancer models P, R Stress and proliferation signaling Direction varies substantially with cell type, concentration, and endpoint; individual MAPKs should be entered separately where primary studies establish direction.
11 NRF2 antioxidant response ↔ or context-dependent NRF2 ↑; HO-1 ↑; antioxidant defense ↑ R, G Secondary cytoprotection Best supported as a normal-tissue antioxidant mechanism. It should not be listed as a uniformly activated anticancer pathway because tumor NRF2 activation could theoretically protect malignant cells in some contexts.
12 Chemosensitization and radiosensitization Chemosensitivity ↑; radiosensitivity ↑ (model-dependent) Potential normal-tissue protection reported in selected chemotherapy injury models G Treatment response modulation Reported with 5-FU and cisplatin and in radiation experiments, but evidence remains preclinical and combination-specific.
13 Clinical Translation Constraint Effective experimental concentrations commonly in the tens of µM Systemic exposure limited by solubility and rapid conjugation G Exposure limitation Poor aqueous solubility, extensive glucuronidation/sulfation, uncertain human tumor exposure, and absence of oncology trials limit direct translation of in-vitro findings.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr





Alzheimer’s disease relevance: Magnolol has significant preclinical AD relevance but no established clinical efficacy. In transgenic AD mouse models it improved cognitive performance and reduced amyloid pathology, while mechanistic studies implicate AMPK/mTOR/ULK1-dependent autophagy, reduced neuroinflammation, modulation of APP/Aβ processing, improved synaptic-protein expression, and protection against Aβ-induced tau hyperphosphorylation and neuronal apoptosis. These findings remain preclinical.

Primary AD mechanisms: Promotion of autophagic clearance through AMPK/mTOR/ULK1 signaling currently has particularly direct mechanistic support. Additional mechanisms include ↓ Aβ burden, ↓ neuroinflammation, preservation of synaptic proteins, and CHRM1/cAMP/PKA/CREB-mediated reduction of Aβ-associated tau hyperphosphorylation and neuronal apoptosis.

Magnolol Alzheimer’s Disease Mechanisms

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 AMPK mTOR ULK1 autophagy p-AMPK ↑; p-ULK1 ↑; p-mTOR ↓; LC3-II ↑; Beclin-1 ↑; p62 ↓ Autophagic clearance ↑ Mechanistically supported in APP/PS1 mice and Aβ oligomer cell models; pathway inhibition weakened magnolol protection.
2 Amyloid pathology Aβ burden ↓; Aβ40 ↓; Aβ42 ↓; APP processing modulation Amyloid pathology ↓ Demonstrated in transgenic mouse models; not established clinically.
3 Neuroinflammation Microglial activation ↓; astrocyte activation ↓; TNF-α ↓; IL-1β ↓; IL-6 ↓; IL-10 ↑ Neuroinflammatory signaling ↓ Observed in AD mouse models and consistent with magnolol's broader anti-inflammatory pharmacology.
4 CHRM1 cAMP PKA CREB and tau CHRM1 ↑; cAMP/PKA/CREB ↑; tau hyperphosphorylation ↓ Neuronal protection Primarily cell-model evidence; useful mechanistic target but lower translational weight than the animal AD data.
5 Synaptic integrity PSD93 ↑; PSD95 ↑; synapsin-1 ↑; synaptophysin ↑ Synaptic function preservation Associated with improved cognition in transgenic AD mice.
6 Neuronal apoptosis Bax ↓; cleaved caspase-9 ↓; Bcl-2 ↑ Apoptosis ↓ Direction contrasts appropriately with the pro-apoptotic effect observed in many cancer-cell models.


Scientific Papers found: Click to Expand⟱
4527- MAG,    Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway
- in-vitro, ESCC, TE1 - in-vitro, ESCC, Eca109 - vitro+vivo, SCC, KYSE150
TumCP↓, TumCMig↓, MMP2↓, Apoptosis↑, cl‑Casp3↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑p38↓, TumCG↓,
4528- MAG,    Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
- Review, Nor, NA
*Inflam↑, *cardioP↑, *angioG↓, *antiOx↑, *neuroP↑, *Bacteria↓, AntiTum↑, TumCG↓, TumCMig↓, TumCI↓, Apoptosis↑, E-cadherin↑, NF-kB↓, TumCCA↑, cycD1/CCND1↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCG↓, Casp3↑, NF-kB↓, Akt↓, mTOR↓, LDH↓, Ca+2↑, Synergy↑, *toxicity↓, *BioAv↝, *PGE2↓, *TLR2↓, *TLR4↓, *MAPK↓, *PPARγ↓,
4529- MAG,    Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities—A Review
- Review, Diabetic, NA
*AntiDiabetic↑, *glucose↓, *SOD↑, *Catalase↑, *ROS↓, *MDA↓, *GPx↑, *CYP2E1↓, *AGEs↓, *IL10↑, *neuroP↑, *GutMicro↑,
4530- MAG,    Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas
- in-vitro, Oral, NA
CSCs↓, ChemoSen↑,
4531- MAG,    Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway
- in-vitro, CRC, HCT116
Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, p‑AMPK↑, Bcl-2↓, P53↑, BAX↑, Cyt‑c↑, TumCMig↓, TumCI↓,
4532- MAG,  Cisplatin,    Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation
- in-vivo, Var, NA
cachexia↓, *IGF-1↑, chemoP↑, *M2 MC↑,
4533- MAG,    Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways
- in-vitro, GC, SGC-7901
AntiCan↑, DNAdam↑, Apoptosis↑, TumCCA↑, Bax:Bcl2↑, MMP↓, Casp3↑, PI3K↓, Akt↓,
4534- MAG,    Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells
- in-vitro, Liver, HepG2 - in-vitro, CRC, COLO205
AntiCan↑, Apoptosis↑, selectivity↑, Ca+2↑, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓,
4535- MAG,  5-FU,    Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
- in-vitro, Cerv, NA
ChemoSen↑, TumCP↓, vinculin↓, TumCA↓, TumCMig↓, TumCI↓, p‑Akt↓, p‑PI3K↓, mTOR↓, E-cadherin↑, β-catenin/ZEB1↑, Snail↓, Slug↓,
4536- MAG,    Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis
- in-vitro, Liver, HepG2 - in-vivo, CRC, COLO205
AntiCan↑, selectivity↑, TumCCA↑, P21↑, Apoptosis↑,
4537- MAG,    Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action
- in-vivo, Melanoma, NA - in-vitro, Melanoma, A431
*cl‑Casp8↑, *PARP↑, *P21↑, tumCV↓, TumCP↓, TumCCA↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK4↓, CDC2↓, P21↑, Apoptosis↑,
5252- MAG,    Insights on the Multifunctional Activities of Magnolol
- Review, Var, NA
BioAv↓, *Inflam↓, *Bacteria↓, *antiOx↑, *neuroP↑, *cardioP↑, CYP1A1↓, *PPARγ↑, *NF-kB↓, *COX2/PTGS2↓, *iNOS↓, *ROS↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, P21↑, TumCG↓, TumCMig↓, TumCI↓, Ki-67↓, PCNA↓, MMP2↓, MMP9↓, MMP7↓, DNAdam↑, MMP↓, TumCP↓, selectivity↑, PI3K↓, Akt↓, H2O2↓, Hif1a↓, *BDNF↑, *NRF2↑, *AChE↑,
8492- MAG,    Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway
- in-vivo, AD, NA
*Apoptosis↑, *cl‑Casp9↓, *BAX↓, *Bcl-2↓, *p62↓, *LC3II↑, *Beclin-1/ATG6↑, *AMPK↑, *mTOR↑, *ULK1/ATG1↑,
972- MAG,    Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells
- vitro+vivo, Bladder, T24/HTB-9
angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31/PECAM-1↓, CA↓,

Showing Research Papers: 51 to 64 of 64
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 64

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA⇅, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   H2O2↓, 2,   MDA↓, 1,   ox-PrxI↑, 1,   ROS↓, 1,   ROS↑, 7,   SOD↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 1,   compI↓, 1,   ETC↓, 1,   mitResp↓, 1,   mtDam↑, 3,   OXPHOS↓, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   p‑AMPK↑, 1,   HK2↓, 1,   IDO1↓, 1,   TCA↝, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   Apoptosis↑, 19,   mt-Apoptosis↑, 1,   BAD↑, 2,   BAX↑, 5,   Bax:Bcl2↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 1,   BID↑, 1,   Casp↑, 1,   Casp3↑, 12,   cl‑Casp3↑, 2,   Casp6↑, 1,   Casp7↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 2,   Casp9↑, 8,   cl‑Casp9↑, 2,   Cyt‑c↑, 6,   DR5↝, 1,   Endon↑, 1,   Fas↓, 1,   FasL↓, 1,   cl‑GSDME↑, 1,   iNOS↓, 1,   Mcl-1↓, 1,   p38↑, 1,   p‑p38↓, 1,   Pyro↑, 1,   survivin↓, 3,   TumCD↑, 1,   XIAP↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt?, 1,   Akt↓, 10,   Akt↝, 1,   p‑Akt↓, 4,   p‑EGFR↓, 1,   ERK↓, 1,   ERK↝, 1,   p‑ERK↓, 1,   p‑IκB↓, 2,   JAK2↓, 1,   JNK↑, 2,   JNK↝, 1,   p‑JNK↓, 1,   MAPK↓, 2,   MAPK↝, 1,   mTOR↓, 5,   P70S6K↓, 2,   PI3K↓, 6,   PI3K↝, 1,   p‑PI3K↓, 3,   p‑PKCδ↓, 1,   PTEN↓, 1,   PTEN↑, 1,   p‑PTEN↓, 1,   STAT3↓, 5,  

Transcription & Epigenetics(tgid=7) ⓘ

cMyc↓, 1,   DNMT1↓, 1,   FOXO3↓, 1,   H3K4↓, 1,   HDAC↓, 1,   miR-148a↑, 1,   other↝, 1,   tumCV↓, 4,   UTF1↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

MitoP↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 4,   P53↑, 4,   PARP↑, 1,   cl‑PARP↑, 5,   PCNA↓, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 3,   CDK4↓, 3,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 7,   cycE/CCNE↓, 1,   Ki-67↓, 5,   P21↑, 6,   p27/CDKN1B↑, 1,   TumCCA↓, 1,   TumCCA↑, 16,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   CSCs↓, 1,   Ki-67↓, 5,   TOPflash↓, 1,   TumCG?, 2,   TumCG↓, 11,   TumCP↓, 13,  

Migration(tgid=13) ⓘ

CA↓, 1,   Ca+2↑, 3,   E-cadherin↑, 3,   EMT↓, 3,   MMP2↓, 4,   MMP7↓, 5,   MMP9↓, 6,   MMP9↑, 1,   N-cadherin↓, 1,   Slug↓, 1,   Smad1↝, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TGF-β↝, 1,   TumCA↓, 1,   TumCI↓, 12,   TumCMig↓, 10,   TumCMig↑, 1,   TumMeta↓, 2,   uPA↓, 1,   UroPA↓, 1,   Vim↓, 1,   vinculin↓, 1,   β-catenin/ZEB1↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   CD31/PECAM-1↓, 1,   Hif1a↓, 3,   VEGF↓, 3,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 8,   MPT↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   FOXP3↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 10,   NF-kB↝, 1,   p‑NF-kB↓, 1,   p‑p65↓, 1,   TCF↓, 1,   Th17↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↝, 1,   CES1↓, 1,   ChemoSen↑, 6,   CYP1A1↓, 2,   Dose↝, 1,   eff↑, 3,   Half-Life↓, 1,   Half-Life↝, 1,   RadioS↑, 2,   selectivity↑, 8,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

p‑EGFR↓, 1,   IL6↓, 1,   LDH↓, 1,   LDH↑, 1,   NOS2↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 8,   AntiTum↑, 2,   cachexia↓, 1,   chemoP↑, 1,   chemoPv↑, 1,   OS↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,   Weight↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 2,   Ingr↝, 2,  
Total Targets: 189

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 8,   ARE↑, 1,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 1,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 4,   ROS↑, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cAMP↑, 1,   glucose↓, 1,   GSK‐3β↓, 1,   GSK‐3β↑, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 1,   BAX↓, 1,   BAX↑, 1,   Bcl-2↓, 2,   cl‑Casp8↑, 1,   cl‑Casp9↓, 1,   Cyt‑c↑, 1,   iNOS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CREB↑, 1,   ERK↓, 1,   HER2/EBBR2↓, 1,   MAPK↓, 1,   mTOR↑, 1,   PKA↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other?, 1,   other↑, 1,   other↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3II↑, 1,   p62↓, 1,   ULK1/ATG1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 1,   PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CycB/CCNB1↓, 1,   P21↑, 2,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

IGF-1↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   MMP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

AIF1/Iba-1↓, 1,   COX2/PTGS2↓, 1,   IL10↑, 2,   IL1β↓, 1,   IL6↓, 2,   Inflam↓, 8,   Inflam↑, 1,   M2 MC↑, 1,   NeuroI↓, 2,   NF-kB↓, 5,   PGE2↓, 1,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

GFAP↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   AChE↑, 1,   BDNF↑, 2,   CHRM1↑, 1,   PSD95?, 1,   SYN1↑, 1,   SYP↑, 1,   SYT1↑, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,   Aβ↓, 3,   Aβ42↓, 1,   tau↓, 1,   p‑tau↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARγ↓, 1,   PPARγ↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 1,   BioAv↝, 3,   CompStab↑, 2,   CYP1A1↓, 1,   CYP2C6↓, 1,   CYP2E1↓, 1,   Dose?, 1,   Dose↝, 2,   eff↑, 1,   Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

HER2/EBBR2↓, 1,   IL6↓, 2,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiAll↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 2,   cognitive↑, 5,   Learn↑, 1,   memory↑, 1,   neuroP↑, 7,   Stress↓, 1,   toxicity↓, 7,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 6,   GutMicro↑, 1,   Inf↓, 1,  
Total Targets: 106

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:121  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page